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New strategies to facilitate the improvement of physical and integrated biological optimization of high-
precision treatment protocols are an important priority for modern radiation oncology. From a clinical
perspective, as knowledge accumulates from molecular radiobiology, there is a complex and exciting
opportunity to investigate novel approaches to rational patient treatment stratiﬁcation based on action-
able tumor targets, together with the appropriate design of next-generation early-phase radiotherapy tri-
als utilizing targeted therapeutics, to formally evaluate relevant clinical and biomarker endpoints. A
unique aspect in the development pathway of systemic agents with presumed radiosensitizing activity
will also be the need for special attention on patient eligibility and the rigorous deﬁnition of radiation
dose–volume relationships and potential dose-limiting toxicities. Based on recent experience from sys-
tematically investigating histone deacetylase inhibitors as radiosensitizing agents, from initial studies
in preclinical tumor models through the conduct of a phase I clinical study to evaluate tumor activity
of the targeted agent as well as patient safety and tumor response to the combined treatment modality,
this communication will summarize principles relating to early clinical evaluation of combining radio-
therapy and targeted therapeutics.
 2013 The Authors. Elsevier Ireland Ltd. Radiotherapy and OncologyOpen access under CC BY-NC-ND license. 
3) 3–16With current advances in molecular radiobiology, strategies for
improving the efﬁcacy of clinical radiotherapy are increasingly fo-
cused on exploiting actionable tumor-speciﬁc molecular targets
(Table 1). Conceptually, it is likely, given the mechanism of action,
that a number of currently available targeted therapeutics may be
expected to modulate one or more of the phenomena described by
‘the 5Rs’ of classic radiobiology and thereby have the potential to
enhance tumor radiosensitivity [97]. On review of almost 100 re-
cent early-phase trials that have examined radiotherapy combined
with targeted therapeutics, a number of actionable tumor signaling
pathways involved in tumor proliferation, angiogenesis, and hy-
poxia were found to have been modulated, with tolerability, safety,
and efﬁcacy as study endpoints. Of note, in these trials, treatment
outcome was diverse, ranging from tolerable to signiﬁcant toxici-
ties, and from lack of additional via signiﬁcant responses to unex-In the context of ‘the 5Rs’, an important hallmark ofmanymalig-
nancies is tumor hypoxia, recognized as one of the determinants
contributing to clinical radiation resistance, that could potentially
be counteractedby therapeutic targetingof hypoxia-dependentper-
turbations [98]. One rational and appealing strategy for improving
radiation efﬁcacy is via the inhibition of hypoxia-driven tumor sig-
nalingbyhistonedeacetylase (HDAC) inhibitors [99,100]. Treatment
with HDAC inhibitors leads to acetylation of histone and non-his-
tone proteins, and the resultant changes in gene transcription cause
alterations in keymolecules that orchestrate awide range of cellular
functions, including cell cycle progression, DNA damage signaling
and repair, and cell death by apoptosis and autophagy [101–104].
Speciﬁcally, HDAC inhibition has been shown to suppress hypoxia-
induced activation of the transcription factor hypoxia-inducible fac-
tor type 1a, thereby counteracting angiogenesis and other tumor
processes directly stimulated by a hypoxic microenvironment
[99,100]. In the clinical context, investigations using HDAC inhibi-
tors as single-agent treatment have reported low toxicity and favor-
able safety proﬁles, suggesting that these drugs can be combined
with standard cytotoxic therapies [105,106].
Following the initial demonstration that HDAC inhibitors en-
hanced radiation-induced clonogenic suppression of experimental
in vitro and in vivo colorectal carcinoma models [107–109], the
phase I Pelvic Radiation and Vorinostat (PRAVO) study (ClinicalTri-aken in
Table 1
Early-phase clinical trials combining radiotherapy and targeted therapeutics.
Anatomical
site
Tumor type Molecular drug
target(s)
Other
concomitant
systemic
agent(s)
Radiation dose
fractionation schedule
Therapeutic
intent
Study
endpoint(s)
Study outcome Conclusion Clinical
phase
design
Publication
year(s)
Reference(s)
Central nervous system
GBM VEGF Temozolomide 2.0 Gy once daily/30 days Postoperative Safety and
efﬁcacy
Toxicity and
response
determined
Unclear whether any
additional response
II 2008, 2011 [1,2]
GBM VEGF Temozolomide 1.8 Gy once daily/33 days Postoperative Safety Toxicity determined Safe combination II 2011, 2012 [3,4]
GBM VEGF Temozolomide 1.8 Gy once daily/33 days Postoperative Safety and
efﬁcacy
Toxicity and
response
determined
Active and generally well
tolerated combination
II 2012 [5]
GBM VEGF Temozolomide Not speciﬁed Postoperative Efﬁcacy Response
determined
Active combination II 2012 [6]
GBM VEGFR + PDGFR
(multitargeted agent)
Temozolomide Not speciﬁed Postoperative Tolerability MTD not
determined
Safe combination I 2011 [7]
GBM VEGFR + EGFR + MET
(multitargeted agent)
Temozolomide 1.8–2.0 Gy once daily/30–
33 days
Postoperative Safety and
tolerability
DLT and MTD
determined
Safe combination I 2010 [8]
GBM Thalidomide targets Temozolomide 2.0 Gy once daily/30 days Postoperative Safety and
efﬁcacy
Toxicity and
response
determined
Unclear whether any
additional response
II 2004 [9]
Childhood
glioma
Thalidomide targets None 1.8 Gy once daily/31 days Local disease
control
Efﬁcacy Response
determined
No additional response II 2007 [10]
Childhood
glioma
EGFR None 1.8 Gy once daily/31 days Local disease
control
Tolerability MTD determined Phase II dose of systemic
agent achieved
I 2010 [11]
Childhood
glioma
EGFR None 1.8 Gy once daily/31 days Local disease
control
Safety and
efﬁcacy
Toxicity and
response
determined
Signiﬁcant response II 2011 [12]
Childhood
glioma
RAS None 1.8 Gy once daily/31 days Local disease
control
Safety and
tolerability
DLT and MTD
determined
None I 2008 [13]
Childhood
glioma
RAS None 1.8 Gy once daily/31 days Local disease
control
Safety and
efﬁcacy
Toxicity and
response
determined
No additional response II 2011 [14]
GBM EGFR Temozolomide 2.0 Gy once daily/30 days Postoperative Efﬁcacy Response
determined
No additional response I/II 2008 [15]
GBM EGFR Temozolomide 1.8–2.0 Gy once daily/30–
33 days
Postoperative Efﬁcacy Response
determined
Signiﬁcant response II 2009 [16]
GBM EGFR Temozolomide 2.0 Gy once daily/30 days Postoperative Safety and
efﬁcacy
Excessive DLT
incidence, trial
terminated
Signiﬁcant toxicity and
unexpected early disease
progression
II 2010 [17]
GBM RAS Temozolomide
or none
2.0 Gy once daily/30 days Postoperative Tolerability MTD determined Well tolerated combination I 2011 [18]
GBM mTOR Temozolomide 2.0 Gy once daily/30 days Postoperative Safety and
tolerability
DLT and MTD
determined
Signiﬁcant toxicity I 2010 [19]
GBM mTOR Temozolomide 2.0 Gy once daily/30 days Postoperative Safety and
tolerability
DLT and MTD
determined
Reasonably well tolerated
combination
I 2011 [20]
Brain
metastases
EGFR None 2.0 Gy once daily/20 days/
4 days weekly
Local disease
control
Safety and
efﬁcacy
Toxicity and
response
determined
Active and generally well
tolerated combination
II 2009 [21]
Mainly brain
metastases
VEGFR + PDGFR
(multitargeted agent)
None Various Symptomatic
relief
Safety and
efﬁcacy
Toxicity and
response
determined
Active and generally well
tolerated combination
I 2011 [22]
4
Targeted
drugs
and
radiotherapy
Head/neck
SCC EGFR None 2.2 Gy once daily/28–
30 days
Local disease
control
Safety and
tolerability
Acute grade 3
toxicities in 11 of 13
patients
Signiﬁcant toxicity I 2010 [23]
SCC EGFR None 2.0 Gy once daily/35 days
or 1.2 Gy twice daily/
32 days
Local disease
control
Safety and
efﬁcacy
Toxicity and
response
determined
Phase II dose of systemic
agent determined
I 2001 [24]
SCC EGFR None Not speciﬁed Deﬁnitive/
local disease
control
Safety,
tolerability,
and efﬁcacy
DLT, MTD, and
response
determined
No additional response I/II 2008 [25]
SCC EGFR None or
cisplatin
2.0 Gy once daily/35–
36 days
Deﬁnitive Safety and
tolerability
DLT determined Well tolerated combination I 2007 [26]
SCC EGFR Cisplatin 2.0 Gy once daily/33–
35 days
Deﬁnitive/
local disease
control
Tolerability
and efﬁcacy
MTD not
determined,
response
determined
Active and generally well
tolerated combination
I 2012 [27]
SCC EGFR Cisplatin 2.0 Gy once daily/15 days,
followed by 1.4 Gy twice
daily/15 days
Deﬁnitive Safety and
tolerability
Toxicity and
response
determined
Active and well tolerated
combination
I 2010 [28]
SCC EGFR Docetaxel 1.8 Gy once daily/38 days Local disease
control
Safety and
efﬁcacy
Toxicity and
response
determined
Unclear whether any
additional response
II 2009 [29]
SCC EGFR Paclitaxel 1.8 Gy once daily/37–
42 days
Local disease
control
Safety,
tolerability,
and efﬁcacy
DLT, MTD, and
response
determined
No additional response I 2010 [30]
SCC EGFR Carboplatin
and paclitaxel
1.8 Gy once daily/39 days Deﬁnitive Safety and
efﬁcacy
Toxicity and
response
determined
Active and well tolerated
combination
II 2011 [31]
SCC EGFR 5-FU and
hydroxyurea
1.5 Gy twice daily/24 days,
split course
Local disease
control
Tolerability
and efﬁcacy
Toxicity and
response
determined
Active and reasonably well
tolerated combination
II 2011 [32]
SCC EGFR + ERBB2
(multitargeted agent)
Cisplatin 2.0 Gy once daily/33–
35 days
Deﬁnitive Safety,
tolerability,
and efﬁcacy
DLT, MTD, and
response
determined
Phase II dose of systemic
agent determined
I 2009 [33]
SCC EGFR and VEGF (two
agents)
Cisplatin 1.25 Gy twice daily/
28 days, split course
Deﬁnitive Safety and
efﬁcacy
Toxicity and
response
determined
Signiﬁcant response with 9
late DLTs in 28 patients
I/II 2012 [34]
SCC EGFR and VEGF (two
agents)
Paclitaxel 1.8 Gy once daily/38 days Local disease
control
Safety and
efﬁcacy
Toxicity and
response
determined
Signiﬁcant response without
additional toxicity
II 2011 [35]
SCC EGFR and
proteasome (two
agents)
None 2.0 Gy once daily/35–
37 days
Local disease
control
Safety and
efﬁcacy
Toxicity and
response
determined, trial
terminated
Unexpected early disease
progression
I 2011 [36]
SCC EGFR and COX-2
(two agents)
None 2.2 Gy once daily/32 days Local disease
control
Tolerability
and efﬁcacy
MTD and response
determined
Active combination with 3
late DLTs in 14 patients
I 2011 [37]
SCC VEGF 5-FU and
hydroxyurea
1.8–2.0 Gy once daily/28–
35 days, split course
Local disease
control
Safety and
tolerability
DLT and MTD
determined
9 late DLTs in 43 patients I 2008 [38]
Thorax/mediastinum
NSCLC EGFR None 2.0. Gy once daily/30 days Local disease
control
Safety and
efﬁcacy
Toxicity and
response
determined
Additional toxicity and
additional response
II 2010 [39]
NSCLC EGFR None 2.0. Gy once daily/32 days Local disease
control
Safety Toxicity determined Acceptable toxicity I 2008 [40]
NSCLC EGFR None 2.0. Gy once daily/33 days Local disease
control
Safety and
efﬁcacy
Toxicity and
response
determined
Well tolerated combination II 2011 [41]
(continued on next page)
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Table 1 (continued)
Anatomical
site
Tumor type Molecular drug
target(s)
Other
concomitant
systemic
agent(s)
Radiation dose
fractionation schedule
Therapeutic
intent
Study
endpoint(s)
Study outcome Conclusion Clinical
phase
design
Publication
year(s)
Reference(s)
NSCLC EGFR None 2.5 Gy once daily/16–
20 days, hypofractionated
Local disease
control
Safety and
efﬁcacy
Toxicity and
response
determined
Active and generally well
tolerated combination
II 2011 [42]
NSCLC EGFR None 3 Gy once daily/10–12 days Symptomatic
relief
Safety and
efﬁcacy
Toxicity and
response
determined
Well tolerated combination I 2011 [43]
NSCLC EGFR None or
paclitaxel
2.0. Gy once daily/33 days Local disease
control
Safety and
efﬁcacy
Toxicity and
response
determined
No or signiﬁcant response
without additional toxicity
II 2010 [44]
NSCLC EGFR Docetaxel 2.0. Gy once daily/35 days Local disease
control
Safety and
tolerability
DLT and MTD
determined
Acceptable toxicity I 2010 [45]
NSCLC EGFR Cisplatin 1.8 Gy once daily/25 days,
followed by 2.0 Gy once
daily/9 days
Local disease
control
Safety DLT determined Additional toxicity I 2011 [46]
NSCLC EGFR Carboplatin
and paclitaxel
1.8 Gy once daily/35 days Local disease
control
Safety and
efﬁcacy
Toxicity and
response
determined
Large radiation volumes
correlated with DLT, active
combination
II 2011 [47]
NSCLC EGFR Carboplatin
and paclitaxel
2.0. Gy once daily/37 days Local disease
control
Safety and
efﬁcacy
Toxicity and
response
determined
Acceptable toxicity without
additional response
II 2008 [48]
NSCLC VEGF None 2.0. Gy once daily/33 days Local disease
control
Safety and
tolerability
DLT in 2 of 6
patients, trial
terminated
Signiﬁcant toxicity I 2012 [49]
NSCLC VEGF Carboplatin
and
pemetrexed
1.8 Gy once daily/34 days Local disease
control
Safety and
efﬁcacy
Trial termination for
safety concerns
Signiﬁcant toxicity II 2010 [50]
NSCLC EGFR and VEGF (two
agents)
Carboplatin
and paclitaxel
2.0. Gy once daily/37 days Local disease
control
Safety and
efﬁcacy
Toxicity and
response
determined
Signiﬁcant toxicity I/II 2012 [51]
Small cell lung
carcinoma
VEGF Carboplatin
and irinotecan
1.8 Gy once daily/34 days Deﬁnitive Safety and
efﬁcacy
Excessive DLT
incidence, trial
terminated
Signiﬁcant toxicity II 2010 [50]
NSCLC mTOR Cisplatin 2.0. Gy once daily/30 days Local disease
control
Safety DLT determined Safe combination I 2007 [52]
Breast AC ERBB2 None 2.0. Gy once daily/25 days Preoperative Safety and
efﬁcacy
Toxicity and
response
determined
Safe and active combination II 2010 [53]
Esophageal AC ERBB2 Paclitaxel and
cisplatin
1.8 Gy once daily/28 days Local disease
control
Safety Toxicity determined No additional toxicity I 2004 [54]
Esophageal AC ERBB2 Paclitaxel and
cisplatin
1.8 Gy once daily/28 days Local disease
control
Efﬁcacy Response
determined
No additional response I/II 2007 [55]
Esophageal AC
or SCC
EGFR Tegafur and
oxaliplatin
1.8 Gy once daily/33 days Local disease
control
Safety,
tolerability,
and efﬁcacy
DLT, MTD, and
response
determined
Safe combination with
signiﬁcant response
I 2012 [56]
Esophageal AC
or SCC
EGFR Irinotecan and
cisplatin
1.8 Gy once daily/28 days Local disease
control
Safety and
efﬁcacy
Toxicity and
response
determined, trial
terminated
Signiﬁcant toxicity II 2012 [57]
Esophageal AC EGFR and VEGF (two
agents)
5-FU,
paclitaxel, and
carboplatin
1.8 Gy once daily/25 days Preoperative Safety and
efﬁcacy
Toxicity and
response
determined
No additional response II 2012 [58]
6
Targeted
drugs
and
radiotherapy
Abdomen
Pancreatic AC EGFR Gemcitabine 1.8 Gy once daily/28 days Local disease
control
Safety Toxicity determined Acceptable toxicity I 2011 [59]
Pancreatic AC EGFR Gemcitabine 1.8 Gy once daily/28 days Local disease
control
Safety,
tolerability,
and efﬁcacy
DLT, MTD, and
response
determined
Active and reasonably well
tolerated combination
I 2008 [60]
Pancreatic AC EGFR Gemcitabine 2.0. Gy once daily/15–
19 days
Local disease
control
Safety and
tolerability
DLT and MTD
determined
Phase 2 radiation dose
determined
I 2012 [61]
Pancreatic AC EGFR Capecitabine 1.8 Gy once daily/28 days Preoperative Safety DLT in 6 of 10
patients, trial
terminated
Signiﬁcant toxicity I 2006 [62]
Pancreatic AC EGFR Paclitaxel 1.8 Gy once daily/28 days Local disease
control
Safety and
tolerability
Toxicity determined Acceptable toxicity I 2009 [63]
Pancreatic AC VEGF Capecitabine 1.8 Gy once daily/28 days Local disease
control
Safety and
efﬁcacy
Toxicity and
response
determined
Large radiation volumes
correlated with DLT, no
additional response
II 2009 [64]
Hepatocellular
carcinoma
Thalidomide targets None 2.0. Gy once daily/25 days Local disease
control
Safety and
efﬁcacy
Toxicity and
response
determined
Acceptable toxicity without
additional response
II 2012 [65]
Pelvis
Gastrointestinal
AC
HDAC None 3 Gy once daily/10 days Symptomatic
relief
Safety and
tolerability
DLT and MTD
determined
Safe combination, high
radiation dose-volume
effects contributed to DLT
I 2010,2011 [66,67]
Prostate AC EGFR None 1.8 Gy once daily/28 days,
then 2.0 Gy daily/11 days
Deﬁnitive Safety and
efﬁcacy
DLT in 16 of 42
patients, response
determined
Active combination with
signiﬁcant toxicity
I/II 2010 [68]
Rectal AC EGFR 5-FU 1.8 Gy once daily/28 days Preoperative Safety and
efﬁcacy
Toxicity and
response
determined
Signiﬁcant toxicity and
additional response
I/II 2008 [69]
Rectal AC EGFR 5-FU 1.8–2.0 Gy once daily/25–
28 days
Preoperative Safety and
efﬁcacy
Toxicity and
response
determined
No additional response II 2009 [70]
Rectal AC EGFR Capecitabine 1.8 Gy once daily/28 days Preoperative Safety DLT in 2 of 6
patients, trial
terminated
Signiﬁcant toxicity I 2006 [62]
Rectal AC EGFR Capecitabine 1.8 Gy once daily/25 days Preoperative Safety and
efﬁcacy
Toxicity and
response
determined
No additional response I/II 2007 [71]
Rectal AC EGFR Capecitabine 1.8 Gy once daily/25 days Preoperative Safety and
efﬁcacy
Toxicity and
response
determined
No additional response II 2010 [72]
Rectal AC EGFR 5-FU and
oxaliplatin
1.8 Gy once daily/28 days Preoperative Safety and
efﬁcacy
Toxicity and
response
determined
Signiﬁcant toxicity without
additional response
II 2011 [73]
Rectal AC EGFR Capecitabine
and oxaliplatin
1.8 Gy once daily/28 days Preoperative Safety and
efﬁcacy
Toxicity and
response
determined
No additional response I/II 2008 [74]
Rectal AC EGFR Capecitabine
and irinotecan
1.8 Gy once daily/28 days Preoperative Safety DLT determined Safe combination I 2006 [75]
Rectal AC EGFR Capecitabine
and irinotecan
1.8 Gy once daily/28 days Preoperative Safety and
efﬁcacy
Toxicity and
response
determined
No additional response II 2009 [76]
Rectal AC EGFR Capecitabine
and irinotecan
1.8 Gy once daily/28 days Preoperative Safety and
efﬁcacy
Toxicity and
response
determined
No additional response II 2011 [77]
Rectal AC VEGF 5-FU 1.8 Gy once daily/28 days Preoperative Safety and
efﬁcacy
Toxicity and
response
determined
Safe and active combination I/II 2009 [78]
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Table 1 (continued)
Anatomical
site
Tumor type Molecular drug
target(s)
Other
concomitant
systemic
agent(s)
Radiation dose
fractionation schedule
Therapeutic
intent
Study
endpoint(s)
Study outcome Conclusion Clinical
phase
design
Publication
year(s)
Reference(s)
Rectal AC VEGF Capecitabine 3.4 Gy once daily/15 days,
split-course,
hypofractionated
accelerated
Local disease
control
Safety and
efﬁcacy
Toxicity and
response
determined
Signiﬁcant response I/II 2009 [79]
Rectal AC VEGF Capecitabine 1.8 Gy once daily/28 days Preoperative Safety and
efﬁcacy
Toxicity and
response
determined
Safe and active combination II 2010 [80]
Rectal AC VEGF Capecitabine 1.8 Gy once daily/28 days Preoperative Safety and
efﬁcacy
Toxicity and
response
determined
No additional response II 2011 [81]
Rectal AC VEGF Capecitabine 3.4 Gy once daily/10 days,
hypofractionated
accelerated
Preoperative Safety and
efﬁcacy
Toxicity and
response
determined
Additional toxicity and
additional response
II 2011 [82]
Rectal AC VEGF Capecitabine 1.8 Gy once daily/28 days Preoperative Safety and
efﬁcacy
Toxicity and
response
determined
Safe and active combination II 2012 [83]
Rectal AC VEGF Capecitabine 1.8 Gy once daily/28 days Preoperative Safety and
efﬁcacy
Toxicity and
response
determined
Active combination with
acceptable toxicity
II 2012 [84]
Rectal AC VEGF Capecitabine 1.8 Gy once daily/28 days Preoperative Safety and
efﬁcacy
Toxicity and
response
determined
Additional response and
additional surgical
complications
II 2011 [85]
Rectal AC VEGF Capecitabine 1.8 Gy once daily/25 days Preoperative Safety and
efﬁcacy
DLT in 4 of 8
patients, trial
terminated
Signiﬁcant toxicity II 2012 [86]
Rectal AC VEGF 5-FU and
oxaliplatin
1.8 Gy once daily/28 days Preoperative Safety and
efﬁcacy
DLT in 19 of 25
patients, trial
terminated
Signiﬁcant toxicity without
additional response
II 2012 [87]
Rectal AC VEGF Capecitabine
and oxaliplatin
1.8 Gy once daily/28 days Preoperative Safety and
efﬁcacy
DLT in 5 of 11
patients, response
determined
Active combination with
signiﬁcant toxicity
I 2007 [88]
Rectal AC VEGF Capecitabine
and oxaliplatin
1.8 Gy once daily/28 days Preoperative Safety and
efﬁcacy
Toxicity and
response
determined
Active combination with
acceptable toxicity
II 2012 [89]
Prostate AC VEGF Androgen
deprivation
77.9 Gy in 38 fractions Local disease
control
Safety Toxicity determined 10 late DLTs in 18 patients II 2012 [90]
Prostate AC COX-2 None 2.0 Gy once daily/35–
37 days
Deﬁnitive Safety Toxicity determined No additional toxicity I 2006 [91]
Skin
T-cell
lymphoma
HDAC None Various Symptomatic
relief
Feasibility Measurements of
response
Signiﬁcant response without
additional toxicity
Case
reports
2012 [92]
SCC EGFR None Not speciﬁed Deﬁnitive Safety and
efﬁcacy
Toxicity and
response
determined
Active and well tolerated
combination
II 2012 [93]
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A.H. Ree, D. Hollywood / Radiotherapy and Oncology 108 (2013) 3–16 9sequential patient cohorts exposed to escalating dose levels of the
HDAC inhibitor vorinostat combined with pelvic palliative radio-
therapy for advanced gastrointestinal malignancy, was the ﬁrst to
report on the therapeutic use of an HDAC inhibitor in clinical radio-
therapy. It was designed to demonstrate a number of key questions;
ﬁrstly, whether the investigational agent reached the speciﬁc target
(detection of tumor histone acetylation), secondly, the applicability
of non-invasive tumor response assessment (using functional imag-
ing), and importantly, that the combination of using an HDAC inhib-
itor together with radiation was safe and tolerable.
In general, phase I studies are ﬁrst-in-human explorations of
new therapeutic principles, typically a single-agent systemic com-
pound with the determination of safety being the primary study
objective. By convention, treatment tolerability is deﬁned by
dose-limiting toxicity (DLT) and maximum-tolerated dose (MTD)
[110]. A DLT is a toxic effect related to the treatment and that is
considered unacceptable because of its severity or irreversibility,
or both, and is typically speciﬁed using standardized grading crite-
ria. The assessment of MTD is based on dose escalation and is often
deﬁned as the highest dose level at which no more than one-third
of patients experience DLT. The ultimate goal of a phase I trial is
therefore to establish a recommended dose, which ideally is both
a safe and efﬁcacious dose, that can be subsequently used in fol-
low-up expanded phase II efﬁcacy trials.
In contrast to studies that examine the use of a single com-
pound, the combination of a new systemic agent with radiation
is a more complex trial setting that demands special consideration
of study design and endpoints that reﬂect both radiation effect and
potential independent and overlapping toxicities. Integrating tar-
geted drugs into early-phase radiotherapy trials will also need par-
ticular attention on more stringent deﬁnition of patient eligibility,
including the issue of restricting the study population to an ana-
tomically deﬁned, advanced stage of disease that is treatable with
radiotherapy, the deﬁnition of radiation dose–volume relation-
ships, and the evaluation of normal tissue toxicities. Based on
our recent translational study experiences, this communication
will summarize a number of principles relating to early clinical
evaluations of radiotherapy with targeted therapeutics.Preclinical proof-of-concept
Experimental radiosensitization
A thorough preclinical evaluation is an absolute prerequisite for
the subsequent development of early-phase protocols combining
radiotherapy with targeted therapeutics. The candidate substance
should be evaluated, using appropriate assays in relevant experi-
mental tumor models, to establish evidence of enhancement of
in vitro and in vivo radiation-induced inhibition of clonogenicity,
while at the same time recognizing that preclinical assessment of
radiosensitizing ability is no guarantee that a drug will work in
the clinical situation. Importantly, the ﬁnal decision of further clin-
ical implementation should also take into account that study end-
point deﬁciencies in preclinical models may be speciﬁc for the
species or experimental design and hence, may not necessarily
translate into lack of clinical efﬁcacy.Experimental tumor models
Locally advanced rectal cancer is an example of an ideal model
system to explore the possible role of tumor hypoxia in a deﬁned
clinical context. Whilst randomized studies have highlighted the
central role of neoadjuvant radiotherapy/chemoradiotherapy in
conjunction with surgical resection to eradicate tumor within the
pelvic cavity and improve long-term outcome [111], inherent tu-
mor resistance to the neoadjuvant treatment is seen in a subgroup
10 Targeted drugs and radiotherapyof patients. In regard to the PRAVO study, our systematic investiga-
tion of HDAC inhibitors as radiosensitizing agents was initiated in
experimental in vitro and in vivo human colorectal carcinoma mod-
els, and demonstrated that vorinostat and other HDAC inhibitors
signiﬁcantly enhanced radiation-induced clonogenic suppression
[107–109]. Recently, using the same tumor models, we also dem-
onstrated experimental radiosensitization by vorinostat under
hypoxic conditions [112]. In addition, a range of experimental
studies performed by other investigators have shown that HDAC
inhibitors reduce the capacity of the tumor cells to repair radia-
tion-induced DNA damage, both at the level of damage signaling
and by affecting the major DNA repair pathways [104].Patient eligibility
Non-curative radiotherapy
In the context of combining a systemic targeted agent with
radiotherapy, it is acknowledged that the delivered radiation dose
may on occasion be close to normal tissue tolerance. Any DLT that
causes an interruption in the radiation delivery is likely to have a
negative impact on the probability of tumor control. For that rea-
son, in a trial setting of evaluating tolerability by deﬁning treat-
ment toxicity of a ﬁrst-in-human combination of radiation with a
targeted therapeutic, only patients that are not candidates for
any curative radiotherapy protocol should be regarded as eligible.
In Norway, for example, where the PRAVO study was conducted,
committees for medical and health research ethics as a general
principle will waive approval of ﬁrst-in-human experimental ther-
apeutic approaches in patients with curative intention of standard
treatment; we believe that this will be an approach adopted in
many European and other countries.
To enable correct interpretation of the study data, patients
should be required to have recovered from acute toxicities of any
prior therapy regardless of duration of the preceding period off ac-
tive treatment. On the other hand, cancer patients that are not can-
didates for curative radiotherapy are often in an advanced disease
stage and commonly in need of further treatment, usually pallia-
tive systemic therapy. Therefore, in order to prevent unnecessary
restriction in patient eligibility, study patients should be allowed
to commence treatment they otherwise would have been offered
after completion of the study’s radiotherapy course. However,
any toxicity appearing before the end-of-study evaluation should
be recorded, even if considered to be unrelated to the study treat-
ment, and evaluated for possible interrelations to this, as was done
in the PRAVO study.Curative radiotherapy
Importantly, treatment toxicity from combined-modality tar-
geted therapeutics and radiotherapy will commonly be different
in a palliative regimen compared with an intensiﬁed curative radi-
ation schedule, as further discussed below. Hence, in considering
the clinical implementation of a systemic agent with radiosensitiz-
ing activity following a ﬁrst-in-human testing of safety in a pallia-
tive setting, the combination will require new evaluation in
patients that are candidates for curative protocols. The challenge
of radiotherapy encountering toxicity at the limits of normal tissue
tolerance, particularly when being used as curative modality, must
be speciﬁcally addressed with regard to patient eligibility. In this
setting, it has been suggested to conduct trials in patient groups
with historically poor treatment outcomes, for example locally ad-
vanced lung cancer or pancreatic cancer [113]. Of note in this
regard, one-third of early-phase studies that were identiﬁed with
deﬁnitive or preoperative therapeutic intent reported signiﬁcant
toxicity (Table 1).Tumor location
A standard phase I study conducted to evaluate a single-agent
systemic compound will typically allow a wide range of tumor
types in end-stage disease. In contrast to early-phase safety studies
with systemic therapies, where disease location is less critical for
the evaluation of treatment tolerability, in radiotherapy trials the
anatomical site of the target lesions determines the adjacent organs
at risk. To enable full interpretation of the outcome toxicity data of
early-phase radiotherapy and targeted therapeutics studies, both
the tumor type and the potential anatomical disease site being irra-
diated will need to be clearly speciﬁed within the study’s eligibility
criteria. Additionally, as shown in the PRAVO study and discussed
below, this will ultimately allow the assessment of treatment efﬁ-
cacy and the application of pharmacodynamic biomarkers.Radiotherapy technique and administration
Target volumes and dose–volume constraints
In some studies, it is likely that acute radiation-induced toxici-
ties may comprise a major contribution to the total toxicity proﬁle;
hence, the radiation technique should be reported in detail. As a
minimum, the description should include precise deﬁnitions of
speciﬁc target volumes (gross tumor volume and clinical and plan-
ning target volumes), tumor dose and dose fractionation, overall
treatment time, and dose variations within all relevant organs at
risk. Data deﬁning the relevant dose–volume constraint and
dose–volume histograms should also be made available either in
graphical format or as supplemental information. The study proto-
col may also specify a more sophisticated description of dose–vol-
ume constraints, according to the recent QUANTEC
recommendations [114].
Ultimately, the descriptions of detailed radiation dose–volume
dependencies within the treatment protocol may facilitate identi-
ﬁcation of adverse radiation effects that are separate from toxic ef-
fects of the investigational systemic agent, and also adhere to the
requirement for radiation dose–volume effects to be reported in
a standardized manner. For example, in our experience of the PRA-
VO study, when protocols employ simple or multiﬁeld techniques
that result in unavoidable irradiation of the bowel, moderate to se-
vere acute gastrointestinal toxicity, primarily diarrhea, is observed
in a number of patients. Furthermore, the probability and severity
of such effects increase with the size of the therapeutic target vol-
ume and the dose per fraction [115]. Within the PRAVO study, the
predominant DLTs reported by the study patients were gastroin-
testinal adverse events, representing a toxicity proﬁle of either
vorinostat [105] or indeed radiotherapy to pelvic target volumes.
In this setting, it was difﬁcult to decide whether or not a toxic
event occurring during treatment was greater than might be ex-
pected for either of the therapeutic components, and speciﬁcally
whether the event should be considered a DLT of the systemic
agent [66]. In a reanalysis of the study data, quantiﬁcation of radi-
ation dose–volume effects enabled us to consider a more precise
interpretation of the contribution of vorinostat to the overall toxic-
ity proﬁle [67]. Similar considerations have also been noted by
other investigators (Table 1; [47,64]).Treatment administration
The timing of administration of the systemic drug with regard
to radiation exposure should also be given. This will be important
in examining the utility of any pharmacodynamic biomarker dem-
onstrating the presence of the investigational agent in the radio-
therapy target tissue, and ideally also reﬂecting the general
mechanism of drug action. Within the PRAVO study, tumor histone
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[116]. Importantly, in prior preclinical in vivo studies, we had also
observed that tumor histone acetylation reached a maximum three
hours after intraperitoneal vorinostat injection into experimental
animals [109]. Hence, within the PRAVO study, one patient at each
vorinostat dose level had both a baseline and a repeat tumor
biopsy two-and-a-half hours after the daily oral administration of
vorinostat (on day 3 of the treatment protocol). Of note, histone
acetylation was observed in all on-treatment biopsy samples, con-
ﬁrming that biological drug activity was achieved at the time of the
daily radiation exposure, and supporting the temporal relationship
of delivering the radiotherapy three hours after vorinostat
administration.Endpoints
Dose and toxicity parameters
The ultimate goal of a ﬁrst-in-human therapy trial is to con-
clude with a recommended treatment dose for follow-up expanded
efﬁcacy trials, and in achieving this, a phase I study typically is de-
signed to determine treatment toxicity and tolerability (in terms of
DLT and MTD, respectively) [110,117], as detailed below. For
molecularly targeted agents, the dose that results in a relevant le-
vel of target modulation may differ greatly from the MTD, and gen-
erally, we do not have a good understanding of the relationship
between the MTD and the dose required to achieve the desired
therapeutic effect. An optimum biological dose may be the dose
that meets a predeﬁned level of inhibitory activity on a key target
in the tumor or a surrogate tissue; that is the dose that is associ-
ated with a preselected pharmacodynamic biomarker reﬂecting
the mechanism of drug action. This implies that proof of biological
activity of the investigational agent that is relevant for the radio-
sensitizing ability should be regarded as a main objective in
early-phase radiotherapy trials with targeted therapeutics.
As mentioned above, within the PRAVO study, tumor histone
acetylation was considered to be the mechanism of action con-
ferred by the investigational systemic drug. This was observed in
therapy targets at all dose levels of vorinostat, highlighting that
biological activity was achieved at the lowest examined dose,
and in addition, suggesting that the optimum biological dose on
concomitant use with radiotherapy may be lower than the deter-
mined MTD (second highest dose level).Pharmacodynamic and surrogate response parameters
In general, early-phase therapy studies accrue a limited number
of patients, inevitably with some heterogeneity in cancer types and
disease sites, and any study endpoints beyond treatment safety
and tolerability may therefore lack strength. Nevertheless, in any
experimentation using humans, inclusion of additional endpoints
should be encouraged, and patients eligible for and willing to par-
ticipate in a biomarker substudy should be requested to sign a sep-
arate consent regarding the additional procedures.
Pharmacodynamic and surrogate response datamay be collected
by functional imaging as an alternative to tissue biopsy sampling.
This is particularly relevant where biopsies from deep-seated tu-
mors in patientswith advanced disease are hazardous and, if associ-
ated with complications, will place additional suffering onto the
patient or delay the commencement of the therapy. In addition to
ethical concerns pertaining to the requirement for the inclusion of
biopsies in clinical trials, practical issuesmay relate to the availabil-
ity and quantity of the tissue retrieved, and whether the obtained
tissue samples are high-quality research material. Moreover, the
clinical study design as such may be incompatible with high-stan-
dard procedures for biomarker identiﬁcation. If an objective is todetermine mechanisms of action, as opposed to biological activity,
of the investigational agent in the radiotherapy target, tumor spec-
imens for this particularpurpose cannotbe sampledafter thepatient
has commenced the radiation treatment. Any regulatory activity in
on-treatment samples would reﬂect the combined effect of radia-
tion and the systemic drug, and the contribution of the latter would
probably be indiscernible from the effect of the actual accumulated
radiation dose. Instead, studies can be designed such that patients
receive the study drug for a period before starting the radiotherapy
course, for example during the treatment planning period. In that
setting, it is also possible to randomize the patients between the
investigational drug and placebo [113].
Traditionally, in phase I studies testing single-agent systemic
compounds, response measurements have commonly been for-
gone as such evaluations may not be seen as meaningful in patient
populations comprising a wide range of tumor types in end-stage
disease. However, if the study eligibility criteria of an early-phase
radiotherapy trial with a targeted drug employ the recommended
principle that tumor type and anatomical locations of the radio-
therapy target lesions should be restricted, the more homogeneous
patient population that possibly results from this strategy may be
more like a traditional phase II study population and may therefore
enable treatment response evaluation by either conventional
methods or novel investigational approaches. Within the PRAVO
study, comprising a relatively homogenous patient population
with advanced gastrointestinal malignancy manifested adjacent
to or within the pelvic cavity, serial diffusion-weighted magnetic
resonance imaging allowed correlation of the individual patient’s
change in tumor apparent diffusion coefﬁcient with tumor volume
measurements, to evaluate the use of the former modality as a sur-
rogate biomarker of treatment response.Pharmacokinetic parameters
Detailed recording of pharmacokinetic variables is a major
objective in ﬁrst-in-human testing of therapies. Presumably, in
the setting of an early-phase study combining radiotherapy and a
systemic drug, the molecularly targeted compound of interest
has already been thoroughly investigated as single-agent thera-
peutic. If this is the case, pharmacokinetic characteristics are well
known and further analysis may be omitted. On the contrary, there
may be a need to verify the single-agent data when used with
radiotherapy. Conceptually, pharmacokinetic variables might be
affected by organ-based changes following irradiation as any
change in treatment response or adverse effects may be non-linear.
For example, in the early gene therapy work, radiation was found
to increase vector transfection efﬁciency [118]. Moreover, there
is currently a deﬁciency in the knowledge about biological effects
of radiation within low-dose volumes that are inevitably irradiated
when applying advanced technologies. Most systemic compounds
are eliminated by hepatic or renal metabolism, and in a recent
experimental model, it was demonstrated that the off-target radi-
ation dose to the liver signiﬁcantly reduced the bioavailability of
the radiosensitizing drug [119].Design
Dose escalation protocols
The conventional 3 + 3 expansion cohort design remains the pre-
vailing method for conducting ﬁrst-in-human trials in cancer ther-
apy [110,120]. The rationale for the design is pragmatic with regard
to documenting adverse events associated with the administration
of new therapies, as it requires no modeling of the dose-toxicity
curve beyond the classic assumption for cytotoxic agents, including
radiotherapy, that toxicity increases with dose. This design, em-
12 Targeted drugs and radiotherapyployed in the PRAVO study, involves treating cohorts of patients
with gradually increasing doses of the investigational agent. Typi-
cally, patients are enrolled onto sequential dose levels of the drug
from a starting dose and with a deﬁned dose escalation. Often,
one patient is entered at each dose level until moderate symptoms
related to the therapy appear. From a dose level with moderate
symptoms, dose escalation take place for every third evaluable pa-
tient that has completed the preceding level. An individual patient
cohort is expanded up to six if one of the three initial patients expe-
riences a DLT. If two patients at a given dose level experience a DLT,
the MTD is determined as the preceding dose level, provided an ob-
served incidence of DLT in no more than one of the six patients.
In combination with a prescribed radiotherapy schedule, either
the dose in itself or the duration of the investigational systemic
compound may be escalated. With the latter, the objective is to
escalate the number of radiation fractions that are potentially sen-
sitized by the drug with the ultimate goal to combine the two
modalities for the entire radiation course [113]. Hence, a single
drug dose is administered throughout the study, but successive pa-
tients cohorts receive the drug combined with radiotherapy con-
comitantly for progressively longer periods.
Alternatively, dose escalation of the systemic agent may follow
a modiﬁed Fibonacci sequence, in which the dose increments be-
come smaller as the dose increases. A disadvantage of this design,
however, is that it often may involve an excessive number of esca-
lation steps. The application of accelerated titration designs may
compensate for a lengthy trial period and make the study conduct
more efﬁcient. Various types of accelerated dose titration methods
have been described in recent reviews [110,117]. All the methods
are based on an initial rapid increment in doses involving one or
two patients or intrapatient dose escalation, until a DLT or alterna-
tively two moderate toxicities in accordance with a predeﬁned
stopping rule are observed, at which point the dose adjustment
method is converted to a more conservative one and with the pos-
sibility to do dose deescalation during the course of patient enroll-
ment. Alternatively, when the single-agent MTD is already known
and the delivered radiation dose is close to the limits of normal tis-
sue tolerance, which may often be the case, as few as two or three
dose levels of the investigational drug can be used to perform an
efﬁcient and safe phase I trial.
Traditional phase I trial methods are convenient to employ as
they are both simple to implement and safe. A review of dose esca-
lation methods used in clinical practice showed that the vast
majority of phase I trials published have used the 3 + 3 design or
variations [110].Adaptive protocols
An alternative dose ﬁnding method for early-phase trials is to
use statistical models that actively seek a dose level that produces
a prespeciﬁed probability of the chosen endpoint on the basis of
the outcome data from all patients previously treated in the trial.
In this way, adaptive designs check data during the course of the
trial and incorporate this existing information as it accrues, to de-
cide how to treat the next study patient. However, despite the ini-
tial enthusiasm for novel dose-ﬁnding methodologies, such trial
designs are uncommon in clinical trial practice, mainly because
of computational complexity and unfamiliarity with practical
implementation [120]. Recognizing this experience in the trial
community, it remains uncertain to what extent statistical mod-
el-based designs will be applicable to early-phase radiotherapy tri-
als with targeted therapeutics.
In a trial employing a potential radiosensitizing agent, the dem-
onstration of its presence in the radiotherapy target tissue at
achievable drug concentrations by a biomarker reﬂecting its bio-
logical activity may be used to support the selected schedule ofthe combination treatment. As mentioned above, within the PRA-
VO study, histone acetylation was observed in the therapy target
at the lowest dose level of vorinostat, which was far below the
determined MTD. Hence, if an adaptive trial design based on this
biomarker had been applied, information on treatment tolerability
would not have been revealed. Moreover, many biomarkers for no-
vel agents are minimally validated at the time of early-phase clin-
ical trials; thus, a tight adaptation of the trial design to biomarker
examination may be counterproductive.Statistical analysis
Generally, for early-phase trials, the size of the study population
is limited. Thus, the resulting data will usually be solely descrip-
tive. If statistical adaptation is required, the use of standard statis-
tical methods may probably be sufﬁcient.Toxicity recording
Toxicity assessments
In radiotherapy, toxic complications are both common and
acceptable, and late adverse events may be signiﬁcant. Adhering
to the principle that only patients in a non-curative disease setting
should be eligible for initial (ﬁrst-in-human) radiotherapy trials
with targeted therapeutics, the issue of late toxicity may be a less
essential endpoint. However, a systemic agent with radiosensitiz-
ing activity will ultimately need to be evaluated as a component
of a curative treatment regimen, and in this context, late toxicity
is likely to be the major safety consideration dictating the feasibil-
ity of the new combination, as discussed below. Currently, there is
no consensus as to how to balance the risk of late toxicity against
the beneﬁt of developing a new therapeutic concept that may ulti-
mately improve local disease control and survival, other than care-
ful implementation of the new treatment based on interpretation
of outcome data from already conducted studies of radiotherapy
combined with targeted therapeutics in the palliative setting. To
date, late adverse events have been reported in a few trials where
local control was the therapeutic intent (Table 1; [34,37,38,90]).
The Common Terminology Criteria for Adverse Events (CTCAE)
version 3.0 was established as a system for recording acute and
late toxic effects with all types of cancer therapy and to uniform
severity scaling. Close attention was paid to the boundary between
grade 2 and grade 3, demarcating a clearly higher level of severity
[121]. CTCAE grade 3 toxicity reﬂects severe injury and implicates
events that commonly trigger dose reduction or other therapy
adjustments in addition to intensiﬁed supportive care interven-
tion. In radiotherapy, a dose reduction is often manifested as inter-
ruption or premature cessation of the treatment and is likely to
have a negative impact on outcome [122].
In the early-phase trial setting of testing a targeted drug in pa-
tients receiving radiotherapy, any acute CTCAE grade P3 toxicity
related to radiation exposure of normal tissues should be consid-
ered a DLT, as should a treatment delay longer than a predeﬁned
period. Treatment-related adverse events will represent cumula-
tive toxicities, as they generally appear on completion of the treat-
ment course or in the immediate follow-up period, which is
typically associated with radiotherapy. Hence, as was imple-
mented in the PRAVO study, toxicity should be recorded continu-
ously during the duration of the treatment and reexamined for
example two and six weeks after treatment completion to observe
the full course of appearance of the toxicity proﬁle. In line with
this, subsequent patient cohorts should not be treated until the de-
ﬁned evaluation window is closed, and additionally, patients dis-
continuing the investigational drug should be regarded as non-
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protocol.Toxicity issues in follow-up expanded efﬁcacy trials
The PRAVO study also illustrated a central issue with regard to
possible transition to a phase II efﬁcacy study, as one might ques-
tion whether the MTD that was determined for vorinostat in com-
bination with pelvic palliative radiotherapy might be tolerable in
an intensiﬁed curative radiation schedule, for example vorinostat
as an additional component of neoadjuvant chemoradiotherapy
for locally advanced rectal cancer. We believe that the design of
a trial to investigate vorinostat as a possible radiosensitizing agent
with long-term curative pelvic radiotherapy should take into ac-
count both intensity and duration of the phase I toxicity proﬁles
and ideally, to diminish the hazard of treatment interruption
caused by acute toxicity, would have a phase I/II design with a
starting vorinostat dose below the MTD obtained in the PRAVO
study. We equally believe it is important to determine a new
MTD for a long-term schedule, even though the PRAVO study
clearly demonstrated the presence of vorinostat in the radiother-
apy target tissue at dose levels far below the phase I MTD. At the
current stage, it is obviously unknownwhether there may exist lin-
earity in terms of drug doses between tumor histone acetylation
and yet uncharacterized biomarkers of the radiosensitizing action
of the HDAC inhibitor. As long as minimal validation of a mechanis-
tic rationale for using a molecularly targeted compound remains, a
traditional dose escalation study design should prevail.Conclusions
The following summarizes our recommendations on principles
for the design and conduct of early-phase radiotherapy trials with
targeted therapeutics.Preclinical proof-of-concept
The investigational drug should have been proven to facilitate
biological mechanisms of radiosensitization in relevant preclinical
tumor models.Patient eligibility
Study patients should have tumor manifestations within a re-
stricted anatomical location, to provide a relatively homogeneous
patient population that enables the evaluation of relevant treat-
ment toxicity, pharmacodynamic biomarkers, and therapy re-
sponse. For a ﬁrst-in-human evaluation of radiation combined
with a targeted therapeutic, only patients that are not candidates
for any curative radiotherapy protocol should be regarded as eligi-
ble, to avoid compromising the probability of tumor control in
curative treatment should any DLT cause interruption in radiation
delivery.Radiotherapy technique and administration
Description of the target volume and in particular, dose varia-
tions within the organs at risk will be required. In addition, the
temporal relationship of the administered systemic agent and the
radiation course should be given.Endpoints
Types of endpoints should include toxicity (DLT) and tolerabil-
ity (MTD), as well as a suggested optimum biological dose deﬁnedby a pharmacodynamic biomarker reﬂecting the mechanism of
drug action.Design
Either the dose in itself or the duration of the investigational
drug may be escalated, and deescalated, if required, in successive
patient cohorts. The escalation schedule may be adapted to a bio-
marker of the proposed mechanism of drug action.Toxicity recording
The CTCAE version 3.0 or higher is recommended as the toxicity
scoring system, and any grade P3 toxicity should be considered a
DLT, as should a treatment delay beyond a predeﬁned length of
period. Treatment-related adverse events in radiotherapy typically
represent cumulative toxicities; hence, toxicity should be recorded
continuously during the duration of treatment and reexamined
after treatment completion and a prolonged follow-up period,
when expedient, to observe the full course of appearance of the
toxicity proﬁle.
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